• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center
 

Core Facilities

Preclinical Murine Pharmacogenetics

Notable References

1. Alimonti, A., Carracedo, A., Clohessy, J.G., Trotman, L.C., Nardella, C., Egia, A., Salmena, L., Sampieri, K., Haveman, W.J., Brogi, E., Richardson, A.L., Zhang, J., Pandolfi, P.P. Subtle variations in Pten dose determine cancer susceptibility. Nature Genetics 42:454-8, 2010

2. Lin, H.K., Chen, Z., Wang, G., Nardella, C., Lee, S.W., Chan, C.H., Yang, W.L., Wang, J., Egia, A., Nakayama, K.I., Cordon-Cardo, C., Teruya-Feldstein, J., Pandolfi, P.P. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464:373-9, 2010.

3. Alimonti, A., Nardella, C., Chen, Z., Clohessy, J.G., Carracedo, A., Trotman, L.C., Cheng, K., Varmeh, S., Kozma, S.C., Thomas, G., Rosivatz, E., Woscholski, R., Cognetti, F., Scher, H.I., Pandolfi, P.P. A novel type of cellular senescence can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis (2010). Journal of Clinical Investigation 120:681-93, 2010.

4. Carver, B., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., Alimonti, A., Nardella, C., Varmeh, S., Scardino, P., Cordon-Cardo, C., Gerald, W., Pandolfi, P. P. (2009). Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature Genetics 41:619-24, 2009.

5. Carver, B., Tran, J., Chen, Z., Carracedo, A., Alimonti, A., Nardella, C., Gopalan, A., Scardino, P., Cordon-Cardo, C., Gerald, W., Pandolfi, P. P. (2009). ETS rearrangements and prostate cancer initiation. Nature, 457(7231):E1; discussion E2-3, 2009.

6. Nardella, C., Carracedo, A., Alimonti, A., Hobbs, R.M., Clohessy, J.G., Chen, Z., Egia, A., Fornari, A., Fiorentino, M., Loda, M., Kozma, S.C., Thomas, G., Cordon-Cardo, C., Pandolfi P.P.  Differential requirement of mTOR in post-mitotic tissues and tumorigenesis. Science Signaling 2(55):ra2, 2009.

7. Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., Papa, A., Nardella, C., Cantley, L.C., Baselga, J., Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. Journal of Clinical Investigation 118:3065-3074, 2008.

8. Nardella C., Chen Z., Salmena L., Carracedo A., Alimonti A., Egia A., Carver B., Gerald W., Cordon-Cardo C., Pandolfi P. P. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes and Development 22:2172-2177, 2008.